TrialSignal
Clinical trial intelligence report
A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01146327
Status
COMPLETED
Phase
Phase 1
Sponsor
Pfizer
Executive brief
Investment-Ready Snapshot
PF-04620110 is positioned within the competitive landscape of Type 2 diabetes treatments, targeting overweight and obese populations. Given the increasing prevalence of Type 2 diabetes globally, the asset holds significant commercial potential. The trial's completion indicates that Pfizer is advancing its pipeline in this therapeutic area, which is critical for maintaining market share against established players like Novo Nordisk and Sanofi. The collaboration with Bristol-Myers Squibb may enhance development capabilities and market access. However, the competitive landscape remains robust, necessitating a thorough assessment of efficacy and safety data to ensure differentiation.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01146327
Indication
Healthy
Modality
small molecule
Target
PF-04620110 is a novel compound targeting mechanisms involved in glucose metabolism, potentially acting on pathways related to insulin sensitivity and secretion, although specific molecular targets have not been disclosed.
Intervention
PF-04620110, PF-04620110, PF-04620110, PF-04620110, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.